Literature DB >> 17605273

[Sicca syndrome in major collagen diseases].

Carmen Mocanu1, Flori Bârjovanu, Doina Bărăscu.   

Abstract

The purpose of this paper is to diagnose the patients with ocular sicca syndrome in major collagenosis, to evaluate the clinical and histopathological lesions, related to stage of the disease and to establish significant correlations between the different clinical tests for qualitative and quantitative determination of lacrimal tear and the severity of ocular disorders. Dry eye disease is a very common disorder of tear film in collagen diseases. The gender ratio is 6/1 female/man. The most severe dry eye symptoms are also presented at women. The diagnostic and the treatment of dry eye rest difficult because of lack of accepted diagnostic criteria and lack of standardized, specific diagnostic tests. The results of this study have revealed that the ophthalmologic examination is necessary to all the patients with collagenosis who present ocular symptoms. The ophthalmological exam will contain qualitative and quantitative tests of lacrimal evaluation and a methodic biomicroscopic examination of corneo-conjunctival surface without and with vital staining. Rheumatoid arthritis is the collagen diseases which most frequently associates ocular sicca syndrome in mild and medium clinical forms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17605273

Source DB:  PubMed          Journal:  Oftalmologia        ISSN: 1220-0875


  2 in total

1.  Rheumatoid factor and antibodies against citrullinated peptides in Moroccan patients with rheumatoid arthritis: association with disease parameters and quality of life.

Authors:  Yousra Ibn Yacoub; Bouchra Amine; Assia Laatiris; Najia Hajjaj-Hassouni
Journal:  Clin Rheumatol       Date:  2011-08-04       Impact factor: 2.980

2.  Anti-cyclic citrullinated peptide, rheumatoid factor, and ocular symptoms typical of rheumatoid arthritis.

Authors:  Sujit Itty; Jose S Pulido; Sophie J Bakri; Keith H Baratz; Eric L Matteson; David O Hodge
Journal:  Trans Am Ophthalmol Soc       Date:  2008
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.